A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD
{{output}}
Background: Inhibition of hepatic lipogenesis is widely regarded as an effective treatment for metabolic-associated fatty liver disease (MAFLD), although numerous related drugs have failed to reach clinical application. The goal ... ...
